Alnylam Pharmaceuticals

  • Wednesday, March 6, 2019

Alnylam Pharmaceuticals has announced positive topline results from the ENVISION Phase 3 study of Givosiran, an investigational RNAi for the treatment of acute porphyria. The report indicates that Givosiran meets the primary and several secondary endpoints, with significant reduction in annualized rate of porphyria attacks relative to a placebo. 

Alnylam intends to complete filing of the New Drug Application (NDA) in mid-2019. None of this would be possible without YOU – the medical heroes who have participated in the clinical trials. 

Read the full article here: